Voyager Therapeutics, Inc. (VYGR) Advances Gene TherapyVoyager Therapeutics, Inc. (VYGR) is a biotechnology company developing next-generation gene therapies to treat serious neurological diseases. Leveraging its TRACER capsid discovery platform, Voyager is advancing treatments for conditions like Parkinson’s disease, Huntington’s disease, and amyotroph
Voyager Therapeutics, Inc.
No trades
No trades
Peers for comparison
Key facts today
Voyager Therapeutics (VYGR) posted quarterly revenue of $4.01 million, down 70% year over year and below analysts’ $6.35 million estimate. The company reported a net loss of $24.69 million. 1
−1.81 USD
−119.72 M USD
40.37 M USD
51.59 M
Next report date
—
Report period
—
EPS estimate
—
Revenue estimate
—
Company info
Sector
Industry
CEO
Alfred W. Sandrock
Website
Headquarters
Lexington
Founded
2013
IPO date
Nov 11, 2015
ISIN
US92915B1061
CUSIP
92915B106
FIGI
BBG005ZSY233
Identifiers
ISIN US92915B1061
Voyager Therapeutics, Inc. is a clinical-stage gene therapy company, which engages in the development of treatments for severe neurological diseases. Its pipeline of gene therapy programs includes VY-AADC, VY-SOD101, VY-HTT01, VY-FXN01, Tau Program, and VY-NAV01. The company was founded by Guang Ping Gao, Mark A. Kay, Krystof Bankiewicz, and Phillip Zamore in June 2013 and is headquartered in Lexington, MA.
Voyager Therapeutics' ($VYGR) Breakthrough
In a groundbreaking move within the biotechnology sector, Voyager Therapeutics recently announced a strategic licensing deal with Novartis, catapulting its shares up by an impressive 35% in premarket trading. The collaboration involves Novartis making an upfront payment of $100 million to gain excl
Target $ 6.12Voyager Therapeutics (VYGR) has signed an agreement through which Pfizer Inc. (PFE) may exercise options to license novel capsids generated from Voyager's TRACER screening technology to treat certain neurologic and cardiovascular diseases.
Under terms of the deal, Pfizer will have the right to eval
Big News, potential breakoutVoyager Therapeutics, Inc. is a clinical-stage gene therapy company, which engages in the development of treatments for severe neurological diseases. Its pipeline of gene therapy programs includes VY-AADC, VY-SOD101, VY-HTT01, VY-FXN01, Tau Program, and VY-NAV01. The company was founded by Guang Pin
VYGR Breakout Stock Alert UpdateBREAKOUT STOCK ALERT UPDATE
$VYGR - Voyager Therapeutics, Inc. - Common Stock
Initial Alert Price: $8.38
Price High: $7.19
% Gains/Losses: -14.2%
(-29.63% Less Than Expected)
Potential Stop Loss: $6.8305
VYGR is currently trading below our 10% Sell Threshold but we have are watching to determine i
See all ideas
Summarizing what the indicators are suggesting.
Neutral
Neutral
Neutral
An aggregate view of professional's ratings.
Neutral
Neutral
Neutral
Displays a symbol's price movements over previous years to identify recurring trends.
Frequently asked questions
Today, VYGR trades at 1.87 USD.
For broader market analysis, dive into the technicals on the Voyager Therapeutics, Inc. stock price chart and read the latest VYGR news:
– Voyager Therapeutics 3Q 2026: Revenue $4.01M, EPS ($0.4) — 10-Q Summary
– Voyager Therapeutics Q3 collaboration revenue drops, net loss narrows
– VYGR: Lower collaboration revenue, reduced spend and cash runway into Q2 2028 define the quarter
For broader market analysis, dive into the technicals on the Voyager Therapeutics, Inc. stock price chart and read the latest VYGR news:
– Voyager Therapeutics 3Q 2026: Revenue $4.01M, EPS ($0.4) — 10-Q Summary
– Voyager Therapeutics Q3 collaboration revenue drops, net loss narrows
– VYGR: Lower collaboration revenue, reduced spend and cash runway into Q2 2028 define the quarter
Markets don't sleep, here's what's going on with VYGR at the moment:
– Voyager Therapeutics 3Q 2026: Revenue $4.01M, EPS ($0.4) — 10-Q Summary
– Voyager Therapeutics Q3 collaboration revenue drops, net loss narrows
– VYGR: Lower collaboration revenue, reduced spend and cash runway into Q2 2028 define the quarter
See more updates in real-time with our News Flow.
– Voyager Therapeutics 3Q 2026: Revenue $4.01M, EPS ($0.4) — 10-Q Summary
– Voyager Therapeutics Q3 collaboration revenue drops, net loss narrows
– VYGR: Lower collaboration revenue, reduced spend and cash runway into Q2 2028 define the quarter
See more updates in real-time with our News Flow.
Voyager Therapeutics, Inc. is scheduled to release its next earnings report on Nov 10, 2026.
Why it matters:
– Key event: Earnings often drive significant price moves
– Market expectations: Traders watch revenue, EPS, and guidance vs forecasts
– Volatility spike: Price swings can increase before and after the release
How to use it:
– Track upcoming reports in the Earnings Calendar
– Compare actual results with analyst estimates
– Monitor price reaction and volume on Supercharts
Why it matters:
– Key event: Earnings often drive significant price moves
– Market expectations: Traders watch revenue, EPS, and guidance vs forecasts
– Volatility spike: Price swings can increase before and after the release
How to use it:
– Track upcoming reports in the Earnings Calendar
– Compare actual results with analyst estimates
– Monitor price reaction and volume on Supercharts
VYGR stock is 13.66% volatile and has beta coefficient of 1.43.
What it means:
– Volatility: Shows how much the price fluctuates over time
– Beta > 1: More volatile than the market
– Beta < 1: Less volatile, more stable
Important to know:
– Volatility can increase during earnings, news events, or market stress
– Large-cap stocks like VYGR are typically less volatile than smaller companies
Track every detail on Voyager Therapeutics, Inc. stock chart and check out the list of the most volatile stocks — is Voyager Therapeutics, Inc. there?
What it means:
– Volatility: Shows how much the price fluctuates over time
– Beta > 1: More volatile than the market
– Beta < 1: Less volatile, more stable
Important to know:
– Volatility can increase during earnings, news events, or market stress
– Large-cap stocks like VYGR are typically less volatile than smaller companies
Track every detail on Voyager Therapeutics, Inc. stock chart and check out the list of the most volatile stocks — is Voyager Therapeutics, Inc. there?
To understand the VYGR stock performance, it's worth checking price changes for various periods to get the full picture:
– 1 day — +8.43%
– 1 week — +6.57%
– 1 month — −23.57%
VYGR all-time low was 1.68 USD (Oct 30, 2026), and its highest price is 31.91 USD (Mar 5, 2018). Find more dynamics in the Stock Heatmap and on the Voyager Therapeutics, Inc. stock chart.
– 1 day — +8.43%
– 1 week — +6.57%
– 1 month — −23.57%
VYGR all-time low was 1.68 USD (Oct 30, 2026), and its highest price is 31.91 USD (Mar 5, 2018). Find more dynamics in the Stock Heatmap and on the Voyager Therapeutics, Inc. stock chart.
Voyager Therapeutics, Inc. market capitalization is 115.23 M, representing the total value of all its outstanding shares (price × shares outstanding).
What it means:
– Market cap is one of the key ways to classify companies (large-cap, mid-cap, etc.)
– It reflects how investors value the company today
– It changes constantly with stock price movements
What to look at next:
– Market cap trends: Rising cap may signal growth and investor confidence; falling cap can reflect risk or downturns
– Price vs shares: Changes can come from Voyager Therapeutics, Inc. stock price moves or share count (buybacks, issuance)
– Valuation ratios: Compare market cap with revenue and earnings
– Peer comparison: See how Voyager Therapeutics, Inc. stacks up against other companies
What it means:
– Market cap is one of the key ways to classify companies (large-cap, mid-cap, etc.)
– It reflects how investors value the company today
– It changes constantly with stock price movements
What to look at next:
– Market cap trends: Rising cap may signal growth and investor confidence; falling cap can reflect risk or downturns
– Price vs shares: Changes can come from Voyager Therapeutics, Inc. stock price moves or share count (buybacks, issuance)
– Valuation ratios: Compare market cap with revenue and earnings
– Peer comparison: See how Voyager Therapeutics, Inc. stacks up against other companies
The safest way to buy Voyager Therapeutics, Inc. stocks is through a reliable broker. Create an account, fund it, and place a buy order.
You can trade VYGR directly from TradingView:
– Choose a broker: Explore our supported trading partners and pick one that fits your needs
– Compare options: View available brokers side by side to evaluate fees and features
– Connect your account: Open Supercharts, click “Trade”, select your broker, and log in
– Start trading: Place orders without leaving the chart
Tip: If you’re new to trading, try paper trading first — it lets you practice strategies in real market conditions without risking funds.
You can trade VYGR directly from TradingView:
– Choose a broker: Explore our supported trading partners and pick one that fits your needs
– Compare options: View available brokers side by side to evaluate fees and features
– Connect your account: Open Supercharts, click “Trade”, select your broker, and log in
– Start trading: Place orders without leaving the chart
Tip: If you’re new to trading, try paper trading first — it lets you practice strategies in real market conditions without risking funds.
As of Nov 8, 2026, the company has 141 employees.
Why traders follow this data:
– Company scale: Employee count reflects the size and global reach of the business
– Operational footprint: Higher headcount often indicates broader product lines, retail presence, or services
– Trend signal: Changes over time can reflect hiring growth, restructuring, or efficiency improvements
See our rating of the largest employers to find more opportunities.
Why traders follow this data:
– Company scale: Employee count reflects the size and global reach of the business
– Operational footprint: Higher headcount often indicates broader product lines, retail presence, or services
– Trend signal: Changes over time can reflect hiring growth, restructuring, or efficiency improvements
See our rating of the largest employers to find more opportunities.
Investing in Voyager Therapeutics, Inc. depends on your goals, risk tolerance, and market conditions. It’s essential to analyze the stock before making a decision.
First, study Voyager Therapeutics, Inc. financials and track their dynamics on the Fundamental Graphs:
– Business fundamentals: Revenue, earnings, and growth trends
– Valuation: P/E ratio, market cap, and how it compares to peers
– Profitability: Margins, return on equity, and cash flow
– Dividends (if any): Yield, payout ratio, and consistency
Then explore our VYGR technicals – signals based on essential indicators calculations:
– Today — sell
– 1-week — sell
– 1-month — sell
Combine fundamental and technical analysis for better results.
First, study Voyager Therapeutics, Inc. financials and track their dynamics on the Fundamental Graphs:
– Business fundamentals: Revenue, earnings, and growth trends
– Valuation: P/E ratio, market cap, and how it compares to peers
– Profitability: Margins, return on equity, and cash flow
– Dividends (if any): Yield, payout ratio, and consistency
Then explore our VYGR technicals – signals based on essential indicators calculations:
– Today — sell
– 1-week — sell
– 1-month — sell
Combine fundamental and technical analysis for better results.
Voyager Therapeutics, Inc. stock ticker depends on the exchange where it’s listed. On the NASDAQ, its primary exchange, Voyager Therapeutics, Inc. stocks trade under the symbol VYGR.
About tickers:
– Unique identifiers: A ticker is a short code used to find and trade a stock
– Exchange-specific: The same company may have different tickers across exchanges
– Search shortcut: Used on trading platforms, charts, and screeners
Remember:
– Some companies have multiple listings
– Always check the exchange prefix to avoid confusion
Learn how to find your desired assets in our Symbol Search.
About tickers:
– Unique identifiers: A ticker is a short code used to find and trade a stock
– Exchange-specific: The same company may have different tickers across exchanges
– Search shortcut: Used on trading platforms, charts, and screeners
Remember:
– Some companies have multiple listings
– Always check the exchange prefix to avoid confusion
Learn how to find your desired assets in our Symbol Search.
VYGR earnings for the last quarter are −0.40 USD per share, whereas the estimation was −0.48 USD, resulting in a 17.32% surprise. The estimated earnings for the next quarter are −0.42 USD per share.
How to read financials:
– Compare actual vs estimates: Earnings beats or misses often drive price moves
– Watch market reaction: Price response matters as much as the numbers
– Look at forward guidance: Future estimates signal expected growth
– Track trends: Analyze results across multiple quarters, not just one
Follow other essential metrics in Voyager Therapeutics, Inc. financials:
– Revenue growth: Shows business expansion
– Margins (operating, net): Reflect profitability and efficiency
– Free cash flow: Indicates real cash generation
– Debt levels: Impacts financial stability and risk
How to read financials:
– Compare actual vs estimates: Earnings beats or misses often drive price moves
– Watch market reaction: Price response matters as much as the numbers
– Look at forward guidance: Future estimates signal expected growth
– Track trends: Analyze results across multiple quarters, not just one
Follow other essential metrics in Voyager Therapeutics, Inc. financials:
– Revenue growth: Shows business expansion
– Margins (operating, net): Reflect profitability and efficiency
– Free cash flow: Indicates real cash generation
– Debt levels: Impacts financial stability and risk
Voyager Therapeutics, Inc. revenue for the last quarter amounts to 3.17 M USD despite the estimated figure of 4.52 M USD. In the next quarter revenue is expected to reach 6.35 M USD.
How to read this data:
– Compare actual vs estimates: Revenue beats or misses can move the stock
– Watch market reaction: Price response shows how investors interpret results
– Look at growth: Compare with previous quarters and year-over-year data
– Track trends: One quarter matters less than consistent performance
Follow other essential metrics in Voyager Therapeutics, Inc. financials:
– Earnings (EPS): Profitability per share
– Margins (gross, operating): Efficiency and cost control
– Free cash flow: Cash available after expenses
How to read this data:
– Compare actual vs estimates: Revenue beats or misses can move the stock
– Watch market reaction: Price response shows how investors interpret results
– Look at growth: Compare with previous quarters and year-over-year data
– Track trends: One quarter matters less than consistent performance
Follow other essential metrics in Voyager Therapeutics, Inc. financials:
– Earnings (EPS): Profitability per share
– Margins (gross, operating): Efficiency and cost control
– Free cash flow: Cash available after expenses
Yes, you can track Voyager Therapeutics, Inc. financials in yearly and quarterly reports right on TradingView.
Use our Earnings Calendar to never miss important releases and spot opportunities early.
Use our Earnings Calendar to never miss important releases and spot opportunities early.
VYGR net income for the last quarter is −24.47 M USD, while the quarter before that showed −27.94 M USD of net income which accounts for 12.40% change.
How to read this data:
– Track changes: Compare net income across quarters to spot trends
– Watch expectations: Compare with estimates to gauge performance
– Check margins: Net income reflects profitability after all expenses
– Look beyond one quarter: Consistency matters more than a single result
Follow other essential metrics in Voyager Therapeutics, Inc. financials:
– Revenue: Overall business growth
– Earnings per share: Rising EPS over time often points to improving business performance
– Margins (gross, operating): Efficiency and cost control
How to read this data:
– Track changes: Compare net income across quarters to spot trends
– Watch expectations: Compare with estimates to gauge performance
– Check margins: Net income reflects profitability after all expenses
– Look beyond one quarter: Consistency matters more than a single result
Follow other essential metrics in Voyager Therapeutics, Inc. financials:
– Revenue: Overall business growth
– Earnings per share: Rising EPS over time often points to improving business performance
– Margins (gross, operating): Efficiency and cost control
No, Voyager Therapeutics, Inc. does not currently pay dividends to its shareholders.
Instead of distributing profits as cash payments, the company may choose to reinvest earnings back into the business — for example, in growth, innovation, acquisitions, or debt reduction.
What to consider instead:
– Earnings growth: Is the company increasing profitability over time?
– Revenue expansion: Is the business scaling its operations?
– Free cash flow: Does it generate enough cash to potentially support future dividends?
– Share buybacks: Some companies return capital through repurchasing shares instead of dividends
Instead of distributing profits as cash payments, the company may choose to reinvest earnings back into the business — for example, in growth, innovation, acquisitions, or debt reduction.
What to consider instead:
– Earnings growth: Is the company increasing profitability over time?
– Revenue expansion: Is the business scaling its operations?
– Free cash flow: Does it generate enough cash to potentially support future dividends?
– Share buybacks: Some companies return capital through repurchasing shares instead of dividends
VYGR reached its all-time high of 31.91 USD on Mar 5, 2018. Its all-time low was 1.68 USD and was reached on Oct 30, 2026.
Explore the Voyager Therapeutics, Inc. stock price chart to see more price history, and discover companies reaching new all-time highs and lows.
Explore the Voyager Therapeutics, Inc. stock price chart to see more price history, and discover companies reaching new all-time highs and lows.
Voyager Therapeutics, Inc. EBITDA is −113.37 M USD, with an EBITDA margin of −316.50%.
EBITDA is a measure of core operating performance, showing how much profit the company generates from its main business activities before accounting for financing and accounting-related costs.
What it means:
– Operating strength: Helps assess profitability from core operations
– Efficiency signal: Rising EBITDA often reflects improving business performance
– Comparability: Useful for comparing companies with different capital structures
What to look at next in Voyager Therapeutics, Inc. statements:
– Revenue growth: Shows whether the business is expanding
– Net income: Captures full profitability after all expenses
– Free cash flow: Shows actual cash generated
– Debt levels: Important when evaluating earnings quality
EBITDA is a measure of core operating performance, showing how much profit the company generates from its main business activities before accounting for financing and accounting-related costs.
What it means:
– Operating strength: Helps assess profitability from core operations
– Efficiency signal: Rising EBITDA often reflects improving business performance
– Comparability: Useful for comparing companies with different capital structures
What to look at next in Voyager Therapeutics, Inc. statements:
– Revenue growth: Shows whether the business is expanding
– Net income: Captures full profitability after all expenses
– Free cash flow: Shows actual cash generated
– Debt levels: Important when evaluating earnings quality
Analyst forecasts suggest a price range between 8.00 USD and 25.00 USD for VYGR, based on current estimates.
Remember:
– Forecasts show possible scenarios, not guaranteed outcomes
– They're based on multiple analysts’ models and assumptions
– Target prices change with earnings, news, and market conditions
Don't rely on analysts' opinions alone:
– Use technical analysis: Trend, support/resistance, momentum
– Study fundamentals: Revenue, earnings, margins
– Account for market context: News, macro trends, sector performance
Remember:
– Forecasts show possible scenarios, not guaranteed outcomes
– They're based on multiple analysts’ models and assumptions
– Target prices change with earnings, news, and market conditions
Don't rely on analysts' opinions alone:
– Use technical analysis: Trend, support/resistance, momentum
– Study fundamentals: Revenue, earnings, margins
– Account for market context: News, macro trends, sector performance









